Green Cross Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross with three other
pharmaceutical manufacturers in Asia:
China Animal Husbandry Ind.
sales of 4.23 billion Chinese Renmimbi [US$618.91 million]
of which 100%
(603.41 billion Korean Won [US$512.30 million]
of which 88%
was Bio Business Division), and
based in India
(30.90 billion Indian Rupees [US$452.96 million]
of which 73%
Green Cross reported sales of 1.05 trillion Korean Won (US$889.59 million)
December of 2015.
increase of 7.4%
versus 2014, when the company's sales were 975.33 billion Korean Won.
This was the fourth straight year of sales growth at Green Cross.
Sales of Gcjbp saw an increase
that was more than double the company's growth rate: sales were up
39.2% in 2015, from
5.66 billion Korean Won to 7.88 billion Korean Won.
Green Cross also saw significant increases in sales in
Greencross Ms (up 9.8% to 89.30 billion Korean Won)
Greencross Gclabcell (up 11.3% to 34.49 billion Korean Won)
Invacfarm (up 20.7% to 14.92 billion Korean Won)
Greencross Genome (up 29.6% to 2.53 billion Korean Won)
Not all segments of Green Cross experienced an increase in sales in 2015:
sales of Gcam fell 53.8% to 9.26 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).
Green Cross also experienced decreases in sales in
Greencross Hs (down 24.3% to 7.53 billion Korean Won)